News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
29,117 Results
Type
Article (1056)
Company Profile (2)
Press Release (28059)
Section
Business (12588)
Career Advice (84)
Deals (2738)
Drug Delivery (1)
Drug Development (2129)
FDA (437)
Job Trends (519)
News (17127)
Policy (928)
Tag
Academia (45)
Allergies (8)
Alliances (816)
ALS (5)
Alzheimer's disease (15)
Antibody-drug conjugate (ADC) (6)
Approvals (464)
Artificial intelligence (6)
Autoimmune disease (4)
Automation (2)
Bankruptcy (13)
Best Places to Work (462)
Biosimilars (6)
Biotechnology (2)
Bladder cancer (9)
Brain cancer (1)
Breast cancer (12)
Cancer (126)
Cardiovascular disease (15)
Career advice (75)
CAR-T (1)
Cell therapy (14)
Cervical cancer (1)
Clinical research (1949)
Collaboration (25)
Compensation (19)
Complete response letters (1)
COVID-19 (104)
CRISPR (4)
C-suite (6)
Cystic fibrosis (6)
Data (249)
Depression (9)
Diabetes (19)
Diagnostics (379)
Digital health (3)
Drug discovery (4)
Drug pricing (3)
Duchenne muscular dystrophy (25)
Earnings (12584)
Events (1418)
Executive appointments (5)
FDA (670)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (1)
Frontotemporal dementia (3)
Funding (18)
Gene editing (7)
Generative AI (3)
Gene therapy (17)
GLP-1 (34)
Government (163)
Guidances (157)
Healthcare (766)
HIV (1)
Huntington's disease (1)
Immunology and inflammation (7)
Immuno-oncology (1)
Indications (8)
Infectious disease (116)
Inflammatory bowel disease (8)
Influenza (2)
Intellectual property (8)
Interviews (20)
IPO (2412)
IRA (1)
Job creations (88)
Job search strategy (53)
Labor market (3)
Layoffs (9)
Legal (144)
Liver cancer (2)
Lung cancer (18)
Lymphoma (17)
Manufacturing (10)
MASH (5)
Medical device (730)
Medtech (736)
Mergers & acquisitions (370)
Metabolic disorders (37)
Multiple sclerosis (7)
Neurodegenerative disease (5)
Neuropsychiatric disorders (4)
Neuroscience (70)
NextGen: Class of 2026 (126)
Non-profit (49)
Obesity (8)
Opinion (2)
Ovarian cancer (2)
Pain (4)
Pancreatic cancer (4)
Parkinson's disease (11)
Patents (11)
Patient recruitment (6)
Peanut (5)
People (501)
Pharmaceutical (2)
Phase 1 (417)
Phase 2 (740)
Phase 3 (903)
Pipeline (636)
Policy (2)
Postmarket research (102)
Preclinical (169)
Prostate cancer (5)
Radiopharmaceuticals (8)
Rare diseases (25)
Real estate (70)
Regulatory (718)
Reports (4)
Research institute (36)
Resumes & cover letters (10)
RSV (2)
Schizophrenia (12)
Series A (1)
Series B (1)
Service/supplier (1)
Sickle cell disease (5)
Spinal muscular atrophy (10)
Sponsored (1)
Startups (45)
Vaccines (12)
Venture capital (3)
Weight loss (9)
Women's health (5)
Date
Last 7 days (27)
Last 30 days (113)
Last 365 days (1635)
2026 (156)
2025 (1652)
2024 (1828)
2023 (2038)
2022 (2183)
2021 (2878)
2020 (2321)
2019 (1683)
2018 (1240)
2017 (973)
2016 (626)
2015 (998)
2014 (619)
2013 (353)
2012 (374)
2011 (461)
2010 (452)
Location
Africa (27)
Alabama (1)
Arizona (14)
Asia (1564)
Australia (173)
California (624)
Canada (139)
China (25)
Colorado (42)
Connecticut (34)
Delaware (20)
Europe (3871)
Florida (66)
Georgia (19)
Idaho (3)
Illinois (43)
India (4)
Indiana (51)
Japan (22)
Kansas (3)
Kentucky (4)
Louisiana (6)
Maine (5)
Maryland (81)
Massachusetts (421)
Michigan (19)
Minnesota (37)
Missouri (5)
Montana (2)
Nevada (3)
New Hampshire (5)
New Jersey (148)
New York (169)
North Carolina (91)
Northern California (371)
Ohio (14)
Pennsylvania (173)
Puerto Rico (1)
South America (49)
Southern California (217)
Tennessee (4)
Texas (56)
United States (2207)
Utah (16)
Virginia (10)
Washington D.C. (1)
Washington State (60)
Wisconsin (5)
29,117 Results for "117".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Earnings
Lilly’s GLP-1s Mounjaro, Zepbound Push Revenue up 46% in Q4
Mounjaro and Zepbound combined for $11.7 billion in the fourth quarter, which beat analyst consensus of $10.6 billion.
February 4, 2026
·
1 min read
·
Annalee Armstrong
Press Releases
ReviR Therapeutics Receives Orphan Drug Designation from FDA for RTX-117 to Treat Charcot-Marie-Tooth Disease
October 13, 2025
·
3 min read
Press Releases
Cell and Gene Therapy Market Size Rapidly Approaching $117.46 Billion by 2034
June 25, 2025
·
1 min read
Press Releases
RECORDATI: STRONG MOMENTUM OF THE GROUP CONTINUES IN THE FIRST HALF OF 2025 REVENUE +11.7%, EBITDA(1) +9.6%, ADJUSTED NET INCOME(2) +8.9%
July 30, 2025
·
19 min read
Press Releases
Aires Announces Record Q3/2025 Revenue of $7.4 Million and 61% YoY Sales Growth and Discusses Factors Related to Liquidity and Continuing Operations
• Gross Profit increased 73% YoY • Gross Margin increased 500 basis points to 68% • Adjusted EBITDA loss reported at $1.46M vs $1.17M in year-ago quarter • Near-term business objectives are focused on preserving cash, stabilizing operations, and securing the financial resources required to support continuity of operations
November 26, 2025
·
16 min read
Press Releases
Dark Genome Biotech HERVolution Therapeutics Announces $11.7M Series A to Advance Treatments for Cancer & Diseases of Aging
December 19, 2024
·
5 min read
Press Releases
Immunocore announces treatment of first patient in the Phase 1/2 trial of IMC-R117C targeting PIWIL1 in advanced gastrointestinal cancers
December 18, 2024
·
8 min read
Policy
Akeso Announced FDA Clearance of IND for CD47 Monoclonal Antibody (AK117) in Combination with Azacitidine in Myelodysplastic Syndromes
Akeso, Inc. announced that the U.S. Food and Drug Administration has cleared the Company’s Investigational New Drug application for AK117, a next generation CD47 monoclonal antibody in combination with azacitidine for treatment of patients with newly diagnosed higher-risk myelodysplastic syndromes.
September 27, 2023
·
2 min read
Press Releases
U.S. Cardiology Procedures Market Size to Hit USD 117.97 Bn by 2033
June 28, 2024
·
1 min read
Drug Development
Magenta Therapeutics Voluntarily Pauses the MGTA-117 Phase 1/2 Dose-Escalation Clinical Trial to Investigate Drug Safety
Magenta Therapeutics (Nasdaq: MGTA) today announced that the latest participant dosed at the Cohort 3 level (0.08 mg/kg) in the ongoing MGTA-117 Phase 1/2 Dose-Escalation Clinical Trial in relapsed/refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) experienced a Grade 5 Serious Adverse Event (SAE) (respiratory failure and cardiac arrest resulting in death) deemed to be possibly related to MGTA-117.
January 25, 2023
·
3 min read
1 of 2,912
Next
